TW591027B - A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, the preparation process thereof and the pharmaceutical composition comprising the same - Google Patents
A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, the preparation process thereof and the pharmaceutical composition comprising the same Download PDFInfo
- Publication number
- TW591027B TW591027B TW089107633A TW89107633A TW591027B TW 591027 B TW591027 B TW 591027B TW 089107633 A TW089107633 A TW 089107633A TW 89107633 A TW89107633 A TW 89107633A TW 591027 B TW591027 B TW 591027B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- patent application
- polymorph
- polymorphs
- scope
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 5
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 9
- 238000001237 Raman spectrum Methods 0.000 claims abstract description 6
- 238000002329 infrared spectrum Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 229940075894 denatured ethanol Drugs 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000002079 cooperative effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- -1 methyl- Chemical group 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- 238000011049 filling Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
591027 A7 五、發明說明( 本發明係關於新穎的醫藥品,該醫藥品的製備方法及 該醫藥品於醫藥上之用途。 國際專利申請案’公告號碼WO 94/〇5659中揭示某 些具有降血糖及降血脂活性之嘍姚三_衍生物類,包括 5-[4-[2-(N-甲基-N-(2-吼咬基)胺基)乙氧基]节基]嗔峻烷 -2,4-二酮,順式丁浠二酸鹽(下文中亦稱為“化合物 ⑴”)。
國際專利申睛案’公開號碼WO 99/31093,WO 99/31094及WO 99/31095中各揭示個別的式⑴化合物之水 合物。 現今發現化合物(I)係以新穎之多晶形物存在,其特別 適用於IS塊之製備及處理。該新翻式可藉有效,經濟及 可再生之特別適合於大尺寸製劑之製法來製備。 該新穎的多晶形物(‘多晶形物,)亦具有有用的製藥 特1*生且特別的疋其可用來治療及/或預防糖尿病,伴隨著 糖尿病之狀況及其某些併發症。 因此,本發明提供了 5—[4一[2_(N—甲基一N—(2士定基) 胺基)乙氧基]节基]嘆姚―2,4—u式丁烯二酸鹽之 多晶形物,其特點在於: 風 ⑴提供含有在_,1326, 1241,714及669cnfl波峰 的紅外線光譜;及/或 ⑹提供含有在 1581,768, 670, 271 及 2260^·^ 喇曼光譜;及/或 峰的 (iii)提供含有實質上列於表!中之化學位移之波蜂的固 89209a 線 員 工 消 費 社 印 製 -3- 本紙張尺度適用中國國豕標準(CNS)A4規格(210 X 297公釐 591027 A7 五、發明說明(2 ) 體狀悲核磁共振光譜;及/或 (iv)提供含有實質上列於表II中之波峰 繞射(XRPD)圖; 、〜射線粉末 (請先閱讀背面之注意事項再填寫本頁) 於一喜愛的方面,該多晶形物提供實 紅外線光譜。 、、、上如圖I中之 於一喜愛的方面,該多晶形物提供實w 之喇曼光譜。 、上如圖II中 於吾笑的方面,該多晶形物提供實質 之固體狀態核磁共振光譜。 、如圖III中 於一吾愛的方面,該多晶形物提供實質 之X-射線粉末繞射(XRPD)圖。 °圖IV中 本發明包含以純型式分離之多晶形物 :其他物質,例如,已知型式之化合-^^ 因此’於-方面言,本發明提供分離型式之 物0 於另一方面,本發明提供純型式之多晶形物。 於另一方面,本發明提供結晶型式之多晶形物。 經濟部智慧財產局員工消費合作社印製 本發明亦提供一種製備多晶形物的方法,其特點在於 =化口物(I)之生料於含有多至約2·5%重量/體積之水的 各^乙醇中,且為含有多至約2.5%重量/體積之水,例 如,2.5%重量/體積之水的含水變性乙醇中加熱,宜至由 35°C及6(TC,例如4〇它至5〇它,例如至45χ:之溫度範圍 間達一延長的時間,例如65小時,於此時間後多晶形 -4- 本紙張尺細中國規格⑽χ297公爱) 經濟部智慧財產局員工消費合作社印製 591027 A7 _ B7 五、發明說明(3 ) 物由變性乙醇中回收。任意的,可於反應混合物中植入該 多晶形物。 於本發明之另一製法中,化合物(I)係與變性乙醇摻 和,加熱至昇高的溫度,宜在由35°C及60°C,例如4〇°e 至50°C,例如由45°C至47t之溫度範圍間,達一延長的 時間,例如,65小時,於此時間後,多晶形物由溶劑中回 收。任意的,可於反應混合物中植入該多晶形物。 於本發明之另一製法中,將含於含有多至2.5%重量 /體積之水,例如,0.8至2.5%重量/體積之水的變性乙 醇中的化合物(I)之溶液中植入多晶形物,然後冷卻至由2〇 它至25°C之溫度範圍間以提供多晶形物。然後將該多晶形 物由變性乙醇中回收。 於變性乙醇中之化合物(I)的溶液可輕易的藉著將化合 物(I)於昇高之溫度,例如60°c,溶解於所需要量之變性乙 醇中而製得。在吾等管理之下,該後者製法亦可用於前揭 露於WO 99/31093中之含有多至25%重量/重量水合物 之化合物(I)而有效的進行。 多晶形物可容易的由反應溶劑中,例如,變性乙醇, 藉過濾法及隨後之乾燥,宜在昇高溫度,例如45°C時回 收。 於本發明之另一方面亦提供一由本發明之多晶形物製 備化合物(1)(亦為了方便下文中稱為“原多晶形物,, (Original Polymorph))之方法,該製法包括首先於昇高溫 度’宜在由60 C至75 C之範圍,例如於68 C時,製備含 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公爱) -I------I---^-----r---訂------I--線 (請先閱讀背面之注音?事項再填寫本頁} 591027 A7 B7 經濟部智慧財產局員工消費合作社印製 發明說明( 有多晶形物於—含無水乙醇及甲醇之混合物⑽:i體積 /體積)之溶液,且然後將溶液冷卻至周遭溫度,例如20_ 25C ’因而使得原多晶形物結晶出來。 曰/於該製備原多晶形物之製法的較佳型式中,將該含夕 j物於無水乙醇/甲醇混合物中之溶液㈣,通常一旦 該多晶形物_完全溶解且該產生的溶㈣加熱至一昇^ 之溫度,例如,至65t,錢賴溶好以冷卻 : 度,例如,20至25°C。 /皿 夕曰於上述製備該原多晶形物之方法巾,雜液可植入原 夕晶形物,但並非必要。 ’、 化合物(I)係根據已知過程製備,例如那些於w〇 94_9中揭示者。w〇 94/〇5659中所揭示者^ 中作為參考。 + \ 為了避免重覆,本文中所用之“化合物⑴,,一詞 5 [4-[2-(M—曱基—Ν—(2—σ比唆基)胺基)乙氧基忤基]嗔唾烷 一,咎二_,順式丁烯二酸鹽型式,如同於國際專 二 案公開號碼Wo 94/05659中揭示及特性化者。 明 本文中“變性乙醇,,係指含有少量甲醇,通常至多5 %體積/體積甲醇,例如由G9%體積/體積至 體積甲醇之乙醇,例如含有4%甲醇之乙醇。 、 本文中預防伴隨著糖尿病之狀況”一詞包括治療例 素抗性’葡萄糖财受性不良,高胰島素血症及姑娠 糖尿病宜指II型糖尿病。 •6- 本紙張尺度適财關^?TcNS)A4 ^ (21〇 : 297公釐) -----------裝-----r---訂---------線 (請先閱讀背面之注意事項再填寫本頁) 591027 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(5 ) 肥胖Γ遺病之狀況包括高血糖症及胰島素抵抗性及 肥胖症。其他伴隨著糖尿病之狀況包括高血壓,心血管疾 病,尤其是動脈粥樣硬化症,某些進食障礙,特別是在 患伴隨著攝食過少之障礙,例如,神經性厭食症,及伴隨 著攝食過量之障礙,例如,肥胖症及善肌癖厭食症之病患 對於食欲及攝取食物之調節作用。其他伴隨著糖尿病之狀 況包括多囊性卵巢徵候群及膽固醇誘導之姨島素抵抗性。 本文中’伴隨著糖尿病之狀況的併發症包括腎疾病, 尤其是伴隨著II型糖尿病發展之腎疾病,包括糖尿病的腎 病,血管球性腎炎,血管球性硬化,腎病徵候群,高血壓 性腎硬化及腎疾病末期。 如前所述,本發明之化合物具有用的治療特性··本發 明之多晶形物因此可用作為活性治療性物質。 更特別的,本發明係提供多晶形物以用來治療及/或 預防糖尿病,伴隨著糖尿病之狀況及其某些併發症。 該多晶形物可單獨給藥或宜以亦包含製藥上可接受之 載體的醫藥組成物給藥。該多晶形物之製劑及其劑量一般 係如同於國際專利申請案,公開號碼W〇 94/〇5659及w〇 98/55122中為化合物⑴揭示者。 因此,本發明亦提供一包含多晶形物及製藥上為此之 可接受載體的醫藥組成物。 該多晶形物通常係以單位劑量蜇式給藥。 該活性化合物可依任何適當的途徑給藥但經常藉口服 或非經腸胃途徑給藥。為了此等用途,該化合物一般係以 本紙張尺度週用中國國家標準(CNS)A4規格(210 X 297公餐) i φ裝--------訂---------線j (請先閱讀背面之注意事項再填寫本頁) 591027 A7 經濟部智慧財產局員工消費合作社印製 發明說明(6) 合併有1藥龍,轉劑及/或朗劑之醫藥 制,雖然組成物之正確型式自然魏據給藥之模式而 疋0 組成物係藉著摻和而製備且係適用於口服,非經腸胃 給藥或局部給藥,且因此可以為_,膠囊 劑’粉末’顆粒,錠片,糖錠,可重組式粉末,可注^ 可灌注之溶液或懸浮液、栓劑及經皮裝置之型式。由於盆 較便於—般㈣,以口服、給藥組成物較適宜,特別是成型 的口服組成物。 口服給藥狀錠劑及膠囊通常係以單位㈣呈現,且 含有習用賦形劑’例如,黏合劑,充填劑,稀釋劑,成鍵 劑,潤滑劑,肢劑,_,香味劑,及潤關。該鍵劑 可根據技藝熟知之方法包埋。 所使用之適當充填劑包括纖維素,甘露糖醇,乳糖及 其他類似試劑。適當的崩散劑包括澱粉,聚乙烯姆烧酮 及版私衍生物’例如澱粉乙醇酸納。適當的潤滑劑包括, 例如,硬脂酸鎂。適當的製藥上可接受的潤關包括月桂 醯硫酸鈉。 固態口服組成物可藉習用之混合、充填、成鍵等方法 製備。可使用重覆的混合操作而將活傾劑在 填劑之那她錢中充分的分布。當然,此等操 於已知技藝者。 口服液態製劑可以為,例如,水性或油性懸浮液,溶 液,乳化液,糖漿,或酏劑,或可以於使用前與水或其他 -----------^-----r---^---------線 0^- (請先閱讀背面之注意事項再填寫本頁) 591027
經濟部智慧財產局員工消費合作社印製 產物呈現。此等液態製劑可含有習用 音,明m -心竹,例如,山梨糖醇,糖漿,曱基纖維 凝膜成Γ ^基乙基纖維素,減甲基纖維素,硬脂酸銘 糠之可食性脂肪,乳化劑,例如,_脂,山梨 -_早油酸酯,或金合歡膠;非水性載 包含 :叫例如,杏仁油,分餾之挪油二, 甘/由伸丙基乙二醇,或乙基醇之醋類;防腐劑, 歹1 σ ’甲基或丙基對經基苯甲酸s旨或山梨酸,且如果想 要,可含有習用香味劑或染劑。 於非經腸胃給藥時,流體單位劑量型式係製成含有本 發月之化B物及-無||載體。根據載體及濃度,該化合物 可為慾浮或/合解。非經腸胃給藥之溶液一般係藉著將活性 化5物/合解於載體及充填劑中,於填充至適當小瓶或安瓿 刖术又菌並岔封而製備。有利的是,輔助劑 ,例如,局部麻 醉劑,防腐劑及緩衝劑亦溶解於載體中。為了增進穩定 性’可將組成物於充填至小瓶後凍乾並於真空中移除水 份。 非經腸胃給藥之懸浮液實質上係依相同方式製備,除 了活性化合物係懸浮於載體中而代替了溶解且藉著在懸浮 於無菌載體之前暴露於環氧乙烷而殺菌。有利的是,組成 物中含有表面活性劑或潤濕劑以促進活性化合物之均勻分 佈。 此外,此等組成物中可再含有活性試劑,例如,抗高 血壓試劑及利尿劑。 -9- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公蓳) -----------裝-----^----訂---------線 (請先閱讀背面之注意事項再填寫本頁) 591027 A7 B7 五、發明說明(8 ) 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 此外’該多晶形物可與其他抗糖尿病試劑,例如,胰 島素促泌素,例如,磺醯脲,雙胍,例如,米甲酸精 (metformin),α糖苷酶抑制劑,例如,爾卡波斯 (acarbose) ’ /5激動劑,及例如那些揭示於w〇 98/57649, WO 98/57634,WO 98/57635 或 WO 98/57630 中之胰島素 合併使用。其他抗糖尿病試劑,其劑量及給藥之方法如同 於刖公開案中提及者。於該組成中之多晶形物的製劑及其 劑量一般係如同上述公開案中為化合物⑴所揭示者。如同 慣例,該組成物通常會對所關係之醫藥治療寫出或印出用 法指導。 於本文中“製藥上可接受,,一詞包括人類及獸醫用之 化合物,組成物及組成份:例如,“製藥上可接受之鹽,, 一詞包括獸醫可接受之鹽。 本發明又提供-種用來治療及/或預防人類或非人類 哺乳類之糖制,伴_糖尿狀狀狀其某些併發症之 方法,其包括將有效量,無毒性之多晶形物給藥至需要之 人類或非人類哺乳類。 方便的,該活性組成份可如同本文於前所定義之醫藥 組成物般給藥,且此構成本發明之一特別的目的。 於治療及/或預防糖尿病,伴隨著糖尿病之狀況及其 某些併發症時,該多晶形物可以例如那些說明於前之劑量 投服 類 乳類 似之劑量攝取法可適用於治療及/或預防非人 類哺 Μ, —r—^---------ml- (請先閱讀背面之注意事項再填寫本頁) -10- 591027 A7 五、發明說明(9 本發明之另一目的提供多晶形物於製備一種用來治療 及/或預防糖尿病,伴隨著糖尿病之狀況及其某些併發症 之醫藥品的用途。 本發明化合物於上述治療中未顯示出不利的毒性效 應。 下列實例係闡明本發明而非以任何方式限制之。 實例: 實败^ •將一含有化合物(1)(3.0克,如於WO 94/05659中 於變性乙醇中製備(3G.5毫升,水含量2.5%重量/體積)) 之生料於45 C加熱65小時。將產物於45°C過濾並於50°C 真空中乾燥,得到多晶形物(155克)。 f性-2 •於一含有無水乙醇(30毫升,水<0.1%重量/體 積)及甲醇(1.2毫升)之混合物中加入化合物⑴(2 〇〇克)。將 產生的懸浮液加熱至45-7°C並維持於此溫度達65 小時。 將固體於45°C分離出來並於5〇χ:真空中乾燥,得到〇 83 克(41%)多晶形物。 實:將化合物⑴丨6·0克,含有約25%重量/重量揭露 於WO 99/31093水合物)於6〇。〇於變性乙醇(6〇毫升,水 含量0.8%重量/體積)中加熱直到獲得完全溶解。將產生 的溶液冷卻至55°C,植入標的化合物(〇 〇6克),然後冷卻 至20-25 C。將產物過濾出來,用變性乙醇(丨〇毫升)清洗 並於50°C真空中乾燥,得到多晶形物(4.8克,80%)。 實J 4 ••多晶形物轉化為化合物(1)(原多晶形物):將多晶 形物(4.0克)於一含無水乙醇(4〇毫升)及曱醇(〇·4毫升)之 -11 - 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 X 297公董) (請先閱讀背面之注意事項再填寫本頁) 裝-----^----訂---------線· 經濟部智慧財產局員Η消費合作社印製 591027 A7 -----— H7_____ 五、發明說明(10) (請先閱讀背面之注意事項再填寫本頁) 混合物中加熱至68 c直到獲得完全溶解。將產生的溶液過 濾、’再加熱至65C,且然後冷卻至2〇_25〇c。將產物過 濾、’用無水乙醇(8毫升)清洗且於贼真空中乾燥,得到 如WO 94/05659中所揭示之化合物⑴(m克,幻%)。 特徵資料:下列特徵資料係為多晶形物生成者: Α.水份含量 其以〇·08%重量/重量用卡爾費雪(Karl Fischer)裝置 測定。 B.紅外線 多晶形物之礦物油分散作用的紅外線吸收光譜係用尼 古拉710FT-IR分光計於2cm-i解析率得到。數據於lcm-i 區間記錄。所獲得之光譜示於圖1。波峰位置如下:2720, 1750, 1703, 1640, 1618, 1610, 1573, 1541,1529, 1513, 1412, 1400, 1360, 1326, 1309, 1300, 1265, 1241,1213, 1183, 1162, 1112, 1096, 1080, 1068, 1033, 1014, 989, 972, 933, 902, 866, 843, 832, 812, 774, 741,734, 729, 669, 660, 636, 613, 605, 577, 558, 540, 527, 515, 508 及 473cm·1。 C·喇曼 經濟部智慧財產局員工消費合作社印製 該多晶形物之喇曼光譜係經由一玻璃管形瓶用波金爾 曼(Perkin Elmer)2000R分光計於4cm·1解析率而記錄且示 於圖II(X-軸表示強度,Y-軸表示喇曼位移cnT1,1800-200cm·1)。激發係用 Nd : YAG 激光(1064nm)400mW 輸出 功率來達成。波峰位置如下:1749, 1706, 1683, 1611,1581, 1546, 1511,1468, 1445, 1435, 1388, 1361,1327, 1301,1269, -12- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公髮) 591027 經濟部智慧財產局員工消費合作社印製 A7 _B7_ 五、發明說明(Π)
1250, 1229, 1210, 1179, 1149, 1103, 1056, 1036, 1024, 1005, 989, 920, 843, 827, 800, 782, 768, 744, 722, 670, 637, 605, 560, 541,512, 473, 429, 408, 397, 347, 322, 271 及 226cm·1。 D.NMR 多晶形物之90·56ΜΗζ 13C CP-MAS NMR光譜係示於 圖III。化學位移係表列於表i。數據係於周遭溫度及 10kHz自旋頻率在一具1.6ms交叉極化作用及15秒之重 覆時間的布魯克(Bruker)AMX360分光計上記錄。化學位 移等同於在176.4ppm相對於四甲基矽烷之I76.4ppm處所 顯示的甘胺酸測試樣品的羧酸訊號,且具有+/ —0e5ppm 以内之正確性。 未指出波峰。 表I. 多晶形物之13c化學位移 化學位移(ppm) 42.2 112.3 131.5 146.5 172.4 50.7 113.9 134.1 151.4 177.4 55.9 118.8 138.7 158.7 62.7 129.8 140.5 170.3 Ε· 违验末繞射(XRPD) 下圖IV所示為多晶形物之xrpd圖型且表II所示為 多晶形物XRPD角及經計算之晶格間隔特性之摘要。 用〜PW 1710 X-射線粉末繞射儀(Cu X-射線源)依下 列給定之條件來產生粉末圖型: -13- 本紙張尺度適用中國國家標準㈣似4規格(· x 297公餐) -----------•裝----l·---訂---------線Φ (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 591027 A7 B7 五、發明說明(I2) 陽極管: Cu 發生器強度: 40kV 發生器電流: 30mA 起始角: 3.5° 2Θ 終點角: 35.0° 2Θ 步大小: 0.020° 2Θ 每步時間. 2·3秒
表II 多晶形物之X-射線粉末繞射角及經計算之晶格間隔特 性0 繞射角 (° 2Θ) 晶格間隔 (埃) 8.9 9.90 12.0 7.35 14.0 6.32 15.4 5.73 15.9 5.55 16.8 5.26 17.4 5.08 18.1 4.89 19.2 4.60 19.6 4.52 20.0 4.44 20.3 4.37 -14- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----------mp 裝-----^----訂---------線 (請先閱讀背面之注意事項再填寫本頁)
Claims (1)
- 591027 申請專利範圍 A8 B8 C8 D8專利申請案第89107633號iff本^年^^ ROC Patent Application No.891076¾^ 修正之申請專利範圍中文本-附件--- Amended Claims in Chinese - Encl.T!) (民國93年5月;> 曰送呈) (Submitted on Ma> ^ , 2004) 10 15 20 經濟部智慧財產局員工消費合作社印製 25 一種5-[4-[2_(Ν·甲基-Ν-(2_π比啶基)胺基)乙氧基]午基] 喧唑烷-2,4-二酮順丁烯二酸鹽之多晶形物(多晶形 物),其特點在於: (i)提供含有在 1360, 1326, 1241,714 及 669cm]波 峰的紅外線光譜;及/或(ϋ)提供含有在 1581,768, 670, 271 及 226cm·1 波峰 的喇曼光譜;及/或 (W)提供含有實質上列於表I中之化學位移之波峰 的固體狀態核磁共振光譜;及/或 (b)提供含有實質上列於表η中之波峰的射線粉 末繞射(XRPD)圖。 如申請專利範圍第1項之多晶形物,其係提供如圖I 之紅外線光譜。 如申請專利範圍第1項之多晶形物,其係提供如圖π 之拉曼(Raman)光譜。 如申請專利範圍第1項之多晶形物,其係提供如圖 III之固體狀悲核磁共振光譜。 5·如申請專利範圍第1項之多晶形物,其係提供如圖Iv 之固體狀恕核磁共振光譜。 6· 種製備如申清專利範圍第1項之多晶形物之方法, 其特點在於: 2. 3. 4. -16 - 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 X 297公釐) 89209B-接 2^91027 申請專利範 A8 B8 C8 D8 圍 10 15 8. 經濟部智慧財產局員工消費合作社印製 20 9. (a) 將一含有5·[4_[2_(Ν_甲基各(24啶基)胺基)乙氧 基]节基]噻唑烷-2,4-二酮,順式丁烯二酸鹽(以下 亦稱為“化合物(I),,或“原多晶形物”)於含有 夕至約2.5%重量/體積之水之含水乙醇的生料 加熱;之後,由變性乙醇中回收多晶形物;或 (b) 將化合物⑴與變性乙醇摻和,加熱至昇高溫度, 之後,由溶劑中回收多晶形物;或 (C)將於含有多至2.5%重量/體積水分之變性乙醇 的化合物(I)於55°C時植入多晶形物然後冷卻至 由20 c至25 C之溫度範圍間而得到多晶形物; 後將該多晶形物由溶劑中回收。 一種用於治療及/或人類或非人類哺乳類之糖尿 病、伴隨著糖尿病之狀況及其某些併發症之醫藥組成 物其係包含一有效量無毒性之如申請專利範圍第i ^的多晶形物及為其之製藥上可接受的載體。 一種製備如申請專利範圍第6項中所定義之“化合物 ()J:5-[4-(2|甲基)-N- (2“比唆基)胺基;]乙氧 基)下基)嗔唾烧_2,4_二酮順丁婦二酸鹽)之方法, 其包含下列步驟:(i)高溫下製備如申請專利範圍第 1至5項中任—項之多晶形物於絕對乙醇及甲醇之混 口 : : 100:1體積/體積)中的溶液;⑼*溶液冷卻 (111)使化合物r結晶及(iv)回收,化合物r 之晶體。 如申請專利範圍第8項之方法,其又包含以,化合物 -17 - 本紙張尺度適用中關家標準(CNS)A4規格(21() χ 297公 591027 A8 B8 C8 _D8_ 六、申請專利範圍 Γ接種冷卻之溶液。 10. 如申請專利範圍第8或9項之方法,其中高溫係在 60°c至75°C之範圍内。 11. 如申請專利範圍第8或9項之方法,其中冷卻至室溫 5 係表示冷卻至20-25°C範圍内之溫度。 12. 如申請專利範圍第8或9項之方法,其中步驟⑴又 包含在高溫下過濾溶液之步驟。 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909472.4A GB9909472D0 (en) | 1999-04-23 | 1999-04-23 | Novel compounds |
| GBGB9912197.2A GB9912197D0 (en) | 1999-05-25 | 1999-05-25 | Novel pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW591027B true TW591027B (en) | 2004-06-11 |
Family
ID=26315460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089107633A TW591027B (en) | 1999-04-23 | 2000-04-24 | A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, the preparation process thereof and the pharmaceutical composition comprising the same |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6815457B1 (zh) |
| EP (3) | EP1284268B1 (zh) |
| JP (1) | JP2002543075A (zh) |
| KR (1) | KR100744359B1 (zh) |
| CN (1) | CN1208335C (zh) |
| AP (1) | AP1495A (zh) |
| AR (2) | AR023568A1 (zh) |
| AT (2) | ATE382046T1 (zh) |
| AU (1) | AU765498B2 (zh) |
| BG (1) | BG65427B1 (zh) |
| BR (1) | BR0009934A (zh) |
| CA (1) | CA2370258A1 (zh) |
| CO (1) | CO5170424A1 (zh) |
| CY (1) | CY1107238T1 (zh) |
| CZ (1) | CZ20013799A3 (zh) |
| DE (2) | DE60004658T2 (zh) |
| DK (2) | DK1284268T3 (zh) |
| DZ (1) | DZ3155A1 (zh) |
| EA (1) | EA004534B1 (zh) |
| ES (2) | ES2298327T3 (zh) |
| HK (1) | HK1045154B (zh) |
| HR (1) | HRP20010773B1 (zh) |
| HU (1) | HUP0200929A3 (zh) |
| IL (1) | IL146110A0 (zh) |
| MA (1) | MA26785A1 (zh) |
| MX (1) | MXPA01010820A (zh) |
| MY (1) | MY128007A (zh) |
| NO (1) | NO320589B1 (zh) |
| NZ (1) | NZ515163A (zh) |
| OA (1) | OA11871A (zh) |
| PE (1) | PE20010040A1 (zh) |
| PL (1) | PL351686A1 (zh) |
| PT (2) | PT1284268E (zh) |
| RS (1) | RS50114B (zh) |
| SK (1) | SK286423B6 (zh) |
| TR (1) | TR200103061T2 (zh) |
| TW (1) | TW591027B (zh) |
| UA (1) | UA67843C2 (zh) |
| UY (1) | UY26120A1 (zh) |
| WO (1) | WO2000064892A2 (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137940A1 (en) * | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| US6664278B2 (en) | 1997-12-16 | 2003-12-16 | Smithkline Beecham P.L.C. | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| AU765498B2 (en) | 1999-04-23 | 2003-09-18 | Smithkline Beecham Plc | Novel pharmaceutical |
| PL351684A1 (en) * | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
| GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
| US7241895B2 (en) * | 2000-09-26 | 2007-07-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| MXPA03002580A (es) * | 2000-09-26 | 2003-10-15 | Cord Janet I | Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion. |
| AU2002352391A1 (en) * | 2001-12-13 | 2003-06-23 | Smithkline Beecham Plc | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus |
| GB0130511D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2003053962A1 (en) * | 2001-12-20 | 2003-07-03 | Smithkline Beecham Plc | 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus |
| GB0307259D0 (en) * | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| EP1468997A3 (en) * | 2003-04-18 | 2004-11-03 | CHEMI S.p.A. | Polymorphous forms of rosiglitazone maleate |
| GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
| WO2005073227A2 (en) * | 2004-01-28 | 2005-08-11 | Usv Limited | A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate |
| ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| US20090076093A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched rosiglitazone |
| EP2184055A1 (en) | 2008-11-07 | 2010-05-12 | LEK Pharmaceuticals d.d. | Process for preparing solid dosage forms of rosiglitazone maleate |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| GB9124513D0 (en) | 1991-11-19 | 1992-01-08 | Smithkline Beecham Plc | Novel process |
| GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
| US20010044458A1 (en) * | 1994-02-10 | 2001-11-22 | Smithkline Beechamp P.L.C. | Use of insulin sensitisers for treating renal diseases |
| JPH09512249A (ja) | 1994-02-10 | 1997-12-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 腎臓疾患を治療するためのインスリンセンシタイザーの使用 |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| GB9711683D0 (en) | 1997-06-05 | 1997-08-06 | Smithkline Beecham Plc | Composition |
| GB9712866D0 (en) | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
| EP1787646A3 (en) | 1997-06-18 | 2007-10-03 | Smithkline Beecham Plc | Novel method of treatment |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| DE69837089T2 (de) | 1997-06-18 | 2007-06-21 | Smithkline Beecham P.L.C., Brentford | Behandlung der diabetes mit thiazolidindion und sulfonylharnstoff |
| US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| EP0975343A1 (en) | 1997-06-18 | 2000-02-02 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
| US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| US20020045649A1 (en) * | 1997-07-18 | 2002-04-18 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| US20020137940A1 (en) | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| GB9726563D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726568D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726566D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU765498B2 (en) | 1999-04-23 | 2003-09-18 | Smithkline Beecham Plc | Novel pharmaceutical |
| HK1045152A1 (zh) | 1999-04-23 | 2002-11-15 | Smithkline Beecham Plc | 噻唑烷二酮衍生物及其用作抗糖尿病藥的應用 |
| PL351684A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
| MXPA03002580A (es) | 2000-09-26 | 2003-10-15 | Cord Janet I | Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion. |
-
2000
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-19 HK HK02104882.1A patent/HK1045154B/zh not_active IP Right Cessation
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 CA CA002370258A patent/CA2370258A1/en not_active Abandoned
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active Expired - Fee Related
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 EP EP02080320A patent/EP1284268B1/en not_active Expired - Lifetime
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2000-04-19 EP EP07150378A patent/EP1903043A1/en not_active Withdrawn
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/en not_active Ceased
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/xx active
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-19 EP EP00920889A patent/EP1173434B1/en not_active Expired - Lifetime
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
-
2001
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
-
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
-
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100744359B1 (ko) | 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도 | |
| CZ20002206A3 (cs) | Substituovaný derivát thiazolidindionu, způsob jeho přípravy a jeho farmaceutické použití | |
| SK286427B6 (sk) | Polymorfná forma soli 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu s kyselinou maleínovu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie | |
| TWI288749B (en) | Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, the process for preparing the same and pharmaceutical composition comprising the same | |
| CZ20002204A3 (cs) | Hydrát soli 5-[4-[2-/N-methyl-(2-pyridyl)amino/ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou jako farmaceutický prostředek | |
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| CZ20013758A3 (cs) | Nový léčivý přípravek | |
| CN100415741C (zh) | 一种噻唑烷二酮衍生物以及其制备抗糖尿病药的应用 | |
| JP2005515987A (ja) | ロジグリタゾンエディシレート抗糖尿病剤としてのその使用 | |
| KR100917953B1 (ko) | 5-[4-[2-(n-메틸-n-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온의 나트륨염 | |
| EP1305311B1 (en) | Tartrate salt of thiazolidinedione derivative | |
| JP2004505971A (ja) | チアゾリジンジオン誘導体の酒石酸塩 | |
| CZ20023966A3 (cs) | Sůl thiazolidindionu pro léčbu diabetes mellitus | |
| CN1620453B (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
| JP2003535861A (ja) | 医薬用の5−(4−(2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ)ベンジル)チアゾリジン−2,4−ジオン・ヨウ化水素酸塩 | |
| AU2005229687B2 (en) | Tartrate salts of thiazolidinedione derivative | |
| WO2003050111A1 (en) | Toluenesulfonate salts of a thiazolidinedione derivative | |
| NO324598B1 (no) | Tartratsalter av tiazolidindionderivat, fremgangsmate for fremstilling drav, anvendelse derav samt farmasoytisk preparat inneholdende saltet | |
| WO2003053963A1 (en) | Novel pharmaceutical | |
| JP2005513038A (ja) | 5−[4−[2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ]ベンジル]チアゾリジン−2,4−ジオンベンゼンスルホン酸塩;その製造方法;多形体i、iiおよびiii;および医薬上活性な成分としてのその使用 | |
| AU2005229694A1 (en) | Tartrate salt of thiazolidinedione derivative | |
| WO1991018893A1 (fr) | Nouveau derive de 1,4-thiazine et cardiotonique contenant ce compose comme ingredient actif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |